Want to see MDCX full AI Analyst Report?
Top Page
Medicus Pharma Ltd
(NASDAQ:MDCX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.10
▼(-62.69% Downside)
Action:Reiterated
Date:10/09/26
The score is held down primarily by weak financial performance (no revenue, accelerating losses, and sustained cash burn with negative equity) and bearish technicals (price below all major moving averages with weak momentum). Offsetting this modestly are positive corporate developments, including the Pfizer CD228V license, while valuation provides limited support due to negative earnings and no dividend yield.
Positive Factors
Pfizer CD228V License
The Pfizer agreement gives Medicus global rights to an early clinical-stage antibody-drug conjugate and provides access to an established linker-payload platform. Potential milestones, royalties, development funding, and Pfizer’s retained options create strategic validation and could support long-term commercialization if clinical execution succeeds.
Negative Factors
Pre-Revenue Losses
Medicus remains pre-commercial, with no reported revenue and losses widening sharply from approximately $5.3 million in 2023 to $39.1 million on a TTM basis. Without an offsetting revenue stream, continued research and development spending leaves profitability and operating leverage dependent on future clinical progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Pfizer CD228V License
The Pfizer agreement gives Medicus global rights to an early clinical-stage antibody-drug conjugate and provides access to an established linker-payload platform. Potential milestones, royalties, development funding, and Pfizer’s retained options create strategic validation and could support long-term commercialization if clinical execution succeeds.
Read all positive factors
Medicus Pharma Ltd (MDCX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.12M
Dividend YieldN/A
Average Volume (3M)7.36M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-67.36%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.62
Shares Outstanding63,180,610
10 Day Avg. Volume1,591,051
30 Day Avg. Volume7,357,044
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap2.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$4.00Price Target Upside1438.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Medicus Pharma Ltd Business Overview & Revenue Model
Company Description
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the cre...
Medicus Pharma Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -39.23M | -25.23M | -11.16M | 1.80M | -1.17M | -1.94M |
| Net Income | -39.15M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
Balance Sheet | ||||||
| Total Assets | 19.11M | 10.06M | 5.65M | 1.89M | 282.65K | 78.51K |
| Cash, Cash Equivalents and Short-Term Investments | 10.70M | 8.71M | 4.16M | 1.72M | 267.65K | 78.51K |
| Total Debt | 15.25M | 4.00M | 322.27K | 0.00 | 1.53M | 667.93K |
| Total Liabilities | 20.33M | 10.02M | 2.51M | 781.61K | 12.48M | 10.58M |
| Stockholders Equity | -1.24M | -67.55K | 3.13M | 1.11M | -12.20M | -10.51M |
Cash Flow | ||||||
| Free Cash Flow | -22.90M | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Operating Cash Flow | -22.90M | -22.78M | -10.25M | -4.16M | -1.06M | -1.45M |
| Investing Cash Flow | -4.65M | -4.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 38.40M | 31.94M | 12.69M | 5.61M | 1.25M | 882.38K |
Medicus Pharma Ltd Technical Analysis
Negative
0.26
Price Trends
0.22
Negative
0.30
Negative
0.58
Negative
Market Momentum
-0.02
Negative
36.68
Neutral
71.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDCX, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.22, and below the 200-day MA of 0.58, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 36.68 is Neutral, neither overbought nor oversold. The STOCH value of 71.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDCX.
Medicus Pharma Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $13.76M | -0.23 | -67.15% | ― | ― | 57.48% | |
45 Neutral | $11.70M | -1.26 | -47.22% | ― | -91.94% | 55.29% | |
45 Neutral | $18.14M | -1.03 | -64.75% | ― | -62.70% | -121.27% | |
44 Neutral | $15.54M | -0.98 | -748.08% | ― | ― | ― | |
43 Neutral | $10.12M | -0.06 | 9999.00% | ― | ― | -67.36% | |
43 Neutral | $16.95M | -1.72 | -115.00% | ― | ― | ― |
* Healthcare Sector Average
MDCX
Medicus Pharma Ltd
0.10
-2.41
-95.98%
BLRX
Bioline RX Ltd Sponsored ADR
2.21
-1.97
-47.13%
PTN
Palatin Technologies
9.01
1.81
25.14%
DARE
Daré Bioscience
0.77
-1.46
-65.38%
LPCN
Lipocine
1.93
-1.22
-38.73%
CTXR
Citius Pharmaceuticals
0.49
-0.79
-61.88%
Medicus Pharma Ltd Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Medicus Pharma announces major share consolidation plan
Neutral
Oct 7, 2026
Medicus Pharma Ltd. will implement a fifty‑to‑one consolidation of its common shares on October 12, 2026, following shareholder approval granted at its June 3, 2026 annual and special meeting. The move is designed to lift the company&#...
Business Operations and StrategyPrivate Placements and Financing
Medicus Pharma Ends Standby Equity Purchase Agreement
Neutral
Sep 14, 2026
On September 11, 2026, Medicus Pharma Ltd. and YA II PN, LTD. mutually terminated a Standby Equity Purchase Agreement that had allowed the company to issue up to $15 million in common shares, with no outstanding borrowings or shares due at the tim...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Medicus Pharma Announces Equity-Based Bonus Share Issuance
Positive
Sep 11, 2026
On September 4, 2026, Medicus Pharma Ltd. awarded approximately $1.45 million in cash bonuses to certain officers and employees, who all chose to receive the value of these bonuses in restricted common shares instead of cash. Based on the Nasdaq C...
Business Operations and Strategy
Medicus Pharma Secures Global Pfizer License for CD228V
Positive
Sep 3, 2026
On September 2, 2026, Medicus Pharma Ltd., via Medicus Pharma Inc., entered a co-development and license agreement with Pfizer Inc. granting Medicus an exclusive worldwide license to develop, manufacture and commercialize PF-08046031 (CD228V), an ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.